131 related articles for article (PubMed ID: 8971857)
1. Assessment of the biodistribution and metabolism of 5-fluorouracil as monitored by 18F PET and 19F MRI: a comparative animal study.
Brix G; Bellemann ME; Haberkorn U; Gerlach L; Lorenz WJ
Nucl Med Biol; 1996 Oct; 23(7):897-906. PubMed ID: 8971857
[TBL] [Abstract][Full Text] [Related]
2. Mapping the biodistribution and catabolism of 5-fluorouracil in tumor-bearing rats by chemical-shift selective 19F MR imaging.
Brix G; Bellemann ME; Haberkorn U; Gerlach L; Bachert P; Lorenz WJ
Magn Reson Med; 1995 Sep; 34(3):302-7. PubMed ID: 7500866
[TBL] [Abstract][Full Text] [Related]
3. Direct detection of intratumoral 5-fluorouracil trapping using metabolic 19F MR imaging.
Brix G; Bellemann ME; Gerlach L; Haberkorn U
Magn Reson Imaging; 1999 Jan; 17(1):151-5. PubMed ID: 9888408
[TBL] [Abstract][Full Text] [Related]
4. Biochemical modulation of the catabolism and tissue uptake of the anticancer drug 5-fluorouracil by 5-bromovinyluracil: assessment with metabolic (19)F MR imaging.
Brix G; Bellemann ME; Haberkorn U
Magn Reson Med; 1999 Nov; 42(5):936-43. PubMed ID: 10542353
[TBL] [Abstract][Full Text] [Related]
5. [In-vivo 19F-MRS study of 5-fluorouracil (5-FU) metabolism on tumors].
Harada M; Nishitani H; Shirahama T; Koga K; Miura I
Gan To Kagaku Ryoho; 1991 Jan; 18(1):75-80. PubMed ID: 1899014
[TBL] [Abstract][Full Text] [Related]
6. Intra- and extracellular fluorouracil uptake: assessment with contrast-enhanced metabolic F-19 MR imaging.
Brix G; Bellemann ME; Gerlach L; Haberkorn U
Radiology; 1998 Oct; 209(1):259-67. PubMed ID: 9769841
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic analysis of 5-[18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma.
Kissel J; Brix G; Bellemann ME; Strauss LG; Dimitrakopoulou-Strauss A; Port R; Haberkorn U; Lorenz WJ
Cancer Res; 1997 Aug; 57(16):3415-23. PubMed ID: 9270007
[TBL] [Abstract][Full Text] [Related]
8. Selective 19F MR imaging of 5-fluorouracil and alpha-fluoro-beta-alanine.
Brix G; Bellemann ME; Zabel HJ; Bachert P; Lorenz WJ
Magn Reson Imaging; 1993; 11(8):1193-201. PubMed ID: 8271906
[TBL] [Abstract][Full Text] [Related]
9. Drug monitoring of 5-fluorouracil: in vivo 19F NMR study during 5-FU chemotherapy in patients with metastases of colorectal adenocarcinoma.
Schlemmer HP; Bachert P; Semmler W; Hohenberger P; Schlag P; Lorenz WJ; van Kaick G
Magn Reson Imaging; 1994; 12(3):497-511. PubMed ID: 8007780
[TBL] [Abstract][Full Text] [Related]
10. Blocking catabolism with eniluracil enhances PET studies of 5-[18F]fluorouracil pharmacokinetics.
Bading JR; Alauddin MM; Fissekis JD; Shahinian AH; Joung J; Spector T; Conti PS
J Nucl Med; 2000 Oct; 41(10):1714-24. PubMed ID: 11038003
[TBL] [Abstract][Full Text] [Related]
11. Noninvasive determination of the arterial input function of an anticancer drug from dynamic PET scans using the population approach.
Kissel J; Port RE; Zaers J; Bellemann ME; Strauss LG; Haberkorn U; Brix G
Med Phys; 1999 Apr; 26(4):609-15. PubMed ID: 10227363
[TBL] [Abstract][Full Text] [Related]
12. Quantitation of 5-fluorouracil catabolism in human liver in vivo by three-dimensional localized 19F magnetic resonance spectroscopy.
Li CW; Negendank WG; Padavic-Shaller KA; O'Dwyer PJ; Murphy-Boesch J; Brown TR
Clin Cancer Res; 1996 Feb; 2(2):339-45. PubMed ID: 9816177
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of 5-fluorouracil anabolism by methotrexate and trimetrexate in two rat solid tumor models, Walker 256 carcinosarcoma and Novikoff hepatoma, as evaluated by 19F-magnetic resonance spectroscopy.
Katzir I; Shani J; Wolf W; Chatterjee-Parti S; Berman E
Cancer Invest; 2000; 18(1):20-7. PubMed ID: 10701363
[TBL] [Abstract][Full Text] [Related]
14. Effects of hepatic impairment on the metabolism of fructose and 5-fluorouracil, as studied in fatty liver models using in vivo 31P-MRS and 19F-MRS.
Otsuka H; Harada M; Koga K; Nishitani H
Magn Reson Imaging; 1999 Feb; 17(2):283-90. PubMed ID: 10215484
[TBL] [Abstract][Full Text] [Related]
15. Studies on 18F-labeled pyrimidines. Tumor uptakes of 18F-5-fluorouracil, 18F-5-fluorouridine, and 18F-5-fluorodeoxyuridine in animals.
Abe Y; Fukuda H; Ishiwata K; Yoshioka S; Yamada K; Endo S; Kubota K; Sato T; Matsuzawa T; Takahashi T; Ido T
Eur J Nucl Med; 1983; 8(6):258-61. PubMed ID: 6223818
[TBL] [Abstract][Full Text] [Related]
16. Kinetic modeling of 5-fluorouracil anabolism in colorectal adenocarcinoma: a positron emission tomography study in rats.
Bading JR; Yoo PB; Fissekis JD; Alauddin MM; D'Argenio DZ; Conti PS
Cancer Res; 2003 Jul; 63(13):3667-74. PubMed ID: 12839957
[TBL] [Abstract][Full Text] [Related]
17. Studies with positron emission tomography after systemic administration of fluorine-18-uracil in patients with liver metastases from colorectal carcinoma.
Dimitrakopoulou A; Strauss LG; Clorius JH; Ostertag H; Schlag P; Heim M; Oberdorfer F; Helus F; Haberkorn U; van Kaick G
J Nucl Med; 1993 Jul; 34(7):1075-81. PubMed ID: 8315481
[TBL] [Abstract][Full Text] [Related]
18. 19F-[1H] nuclear Overhauser effect and proton decoupling of 5-fluorouracil and alpha-fluoro-beta-alanine.
Krems B; Bachert P; Zabel HJ; Lorenz WJ
J Magn Reson B; 1995 Aug; 108(2):155-64. PubMed ID: 7648013
[TBL] [Abstract][Full Text] [Related]
19. Fluoropyrimidine chemotherapy in a rat model: comparison of fluorouracil metabolite profiles determined by high-field 19F-NMR spectroscopy of tissues ex vivo with therapy response and toxicity for locoregional vs systemic infusion protocols.
Lutz NW; Naser-Hijazi B; Koroma S; Berger MR; Hull WE
NMR Biomed; 2004 May; 17(3):101-31. PubMed ID: 15137037
[TBL] [Abstract][Full Text] [Related]
20. 18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil.
Moehler M; Dimitrakopoulou-Strauss A; Gutzler F; Raeth U; Strauss LG; Stremmel W
Cancer; 1998 Jul; 83(2):245-53. PubMed ID: 9669806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
